Indeed, early clinical trials of monotherapy with the PARP inhibitor olaparib realized much of this promise with RECIST responses in 30–40 % of breast and ovarian cancer patients with BRCA mutations [14, 20]. Here, PARP1 is linked to ovarian carcinoma.